SecProbe.io - Filing

CORRESP Filing

Tonix Pharmaceuticals Holding Corp.
Date: Sept. 3, 2025 · CIK: 0001430306 · Accession: 0001999371-25-012500

View on Edgar

AI Filing Summary & Sentiment

Sentiment

Urgency

Document Type

Confidence

SEC Posture

Company Posture

Summary

Reasoning

File numbers found in text: 333-287965

Date

June 12, 2025

Author

yours

Form

CORRESP

Company

Tonix Pharmaceuticals Holding Corp.

Letter

Tonix Pharmaceuticals Holding Corp.

Main Street, Suite 101

Chatham, New Jersey 07928

September 3, 2025

VIA EDGAR

United States Securities and Exchange Commission

Division of Corporation Finance

F Street, N.E.

Washington, D.C. 20549

Re: Tonix Pharmaceuticals Holding Corp.

Registration Statement on Form S-3 (File No. 333-287965)

Filed on June 12, 2025

Ladies and Gentlemen:

Reference is made to our letter, filed as correspondence via EDGAR on August 29, 2025, in which we requested the acceleration of the effective date of the above-referenced Registration Statement for September 3, 2025, at 4:00 p.m., Eastern Time, in accordance with Rule 461 under the Securities Act of 1933, as amended. We are no longer requesting that such Registration Statement be declared effective at this time and we hereby formally withdraw our request for acceleration of the effective date.

Please call Irina Ishak of Lowenstein Sandler LLP at (973) 422-6406 with any questions.

Very truly
yours,
TONIX PHARMACEUTICALS HOLDINGS CORP.

Show Raw Text

CORRESP
 1
 filename1.htm

 Tonix
Pharmaceuticals Holding Corp.

 26
Main Street, Suite 101

 Chatham,
New Jersey 07928

 September
3, 2025

 VIA
EDGAR

 United
States Securities and Exchange Commission

 Division
of Corporation Finance

 100
F Street, N.E.

 Washington,
D.C. 20549

 Re:
 Tonix
 Pharmaceuticals Holding Corp.

 Registration
 Statement on Form S-3 (File No. 333-287965)

 Filed
 on June 12, 2025

 Ladies
and Gentlemen:

 Reference
is made to our letter, filed as correspondence via EDGAR on August 29, 2025, in which we requested the acceleration of the effective
date of the above-referenced Registration Statement for September 3, 2025, at 4:00 p.m., Eastern Time, in accordance with Rule 461 under
the Securities Act of 1933, as amended. We are no longer requesting that such Registration Statement be declared effective at this time
and we hereby formally withdraw our request for acceleration of the effective date.

 Please
call Irina Ishak of Lowenstein Sandler LLP at (973) 422-6406 with any questions.

 Very truly
 yours,

 TONIX PHARMACEUTICALS HOLDINGS CORP.

 By:
 /s/
 Bradley Saenger

 Name:
 Bradley Saenger

 Title:
 Chief Financial Officer